ADAC Laboratories of Milpitas, CA, pleased the investment communitylast week by announcing that it expects sharply higher bookingsand revenue for its first quarter of fiscal 1996 (end-December).The market responded by sending the nuclear medicine
ADAC Laboratories of Milpitas, CA, pleased the investment communitylast week by announcing that it expects sharply higher bookingsand revenue for its first quarter of fiscal 1996 (end-December).The market responded by sending the nuclear medicine vendor'sstock up 19% to close at $14.13 a share on Jan. 10, a 52-weekhigh.
ADAC said that it expects first-quarter revenues of $54 millionto $55 million, a 24% increase over last year's sales of $44 million.Earnings per share will be about 20¢ versus 15¢ in thesame period last year. Nuclear medicine bookings skyrocketed 61%to $48 million.
In a presentation last week at the Hambrecht & Quist HealthCare Conference in San Francisco, ADAC CEO David Lowe said thecompany's Molecular Coincidence Detection (MCD) technology isdriving new sales and will enable the company to take market sharefrom other vendors and other modalities.
"Over time, (MCD) has the potential not only to improveour market share in our core business, but more importantly todrive additional market opportunities for our core business aswe replace conventional imaging in the staging of cancer patients,"Lowe said.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Suggests CT-Guided Injections May Restore Sense of Smell in Patients with Long COVID
November 20th 2023Utilizing computed tomography (CT) guidance, researchers have found that performing a minimally invasive anesthetic injection into the stellate ganglia may help address parosmia due to COVID-19, according to study results that will be presented at the annual Radiological Society of North America (RSNA) conference next week.